Oncology Data Advisor

The FDA's recent accelerated approval of zanidatamab marks a significant breakthrough in the treatment landscape for human epidermal growth factor receptor 2 (HER2)–positive biliary tract cancer (BTC). Following the approval, Dr. James Harding, Associate Attending Physician in the Gastrointestinal Oncology and Early Drug Development Services at Memorial Sloan Kettering Cancer Center, sat down to p...

As Lung Cancer Awareness Month progresses, this discussion hosted by Oncology Data Advisor sheds light on the advancements in lung cancer therapies, unmet needs, the evolving landscape of molecular testing, and actionable insights for clinicians.

The BENEFIT trial, which studied isatuximab, lenalidomide, dexamethasone, and bortezomib in transplant-ineligible multiple myeloma, was published earlier this year in Nature Medicine. I'll be talking about this as if it was one of my patients coming to me with a copy of this paper in their hand that a friend or loved one forwarded to them. What do I tell them?

Artera: Personalizing Treatment Decisions in Prostate Cancer and Beyond With Waqas Haque, MD, MPH, and Trevor Royce, MD, MS, MPH, FASCO by i3 Health

i3 Health is pleased to invite you to Pathways to Precision: Integrating Genetic Counseling and Testing Into Cancer Care, a free, live webinar held on November 7 at 10:00 am Eastern and November 19 at 11:30 am Eastern. This interview features an exclusive preview from the two webinar co-chairs, Dr. Filipa Lynce, Director of the Inflammatory Breast Center at Dana-Farber Cancer Center and Assistant...

In this episode of Exploring Artificial Intelligence in Oncology, Dr. Waqas Haque, MD, sits down with Aamir Ehsan, MD, the Founder and CEO of CorePath Laboratories in San Antonio, Texas. Together they discuss how CorePath utilizes AI in pathology.

Dr. Deborah Wong, Director of the Medical Oncology Program and Clinical Trials Program for Head and Neck Squamous Cell Cancers (HNSCC) and an Associate Clinical Professor of Medicine at the University of California Los Angeles (UCLA) is currently serving as co-chair of i3 Health’s accredited CME/NCPD activity, Recurrent and Metastatic HNSCC, Harnessing Immunotherapy and Comprehensive Care. With ne...

Jeff Sperry, PharmD, BCPS, a Clinical Pharmacist at UCHealth Memorial Hospital, discusses additional advances in chronic kidney disease since recording the i3Health CPE-accredited activity, Slowing Progression of Chronic Kidney Disease Through Value-Based Care. Following the interview, continue listening for the complete CPE-accredited podcast. Click this link to claim your free CPE certificate: h...

Click here to view the full activity and claim free NCPD credit! https://i3health.com/course-information/managing-immune-related-adverse-events-to-ensure-optimal-cancer-immunotherapy-outcomes-the-nurses-view At last year’s Greater Los Angeles Oncology Nursing Society (GLAONS) Oncology Care Summit, i3 Health hosted a nursing continuing professional development (NCPD) symposium entitled Managing Imm...

In this episode of Exploring Artificial Intelligence (AI) in Oncology, Dr. Waqas Haque sits down with Dana Brown, the President, CEO, and Chairman of the Board at iCAD, a company whose mission is to use innovative AI solutions that empower providers to accurately, reliably, and quickly detect cancer and improve outcomes. Ms. Brown shares more about iCAD’s products and recommendations for how to in...

In this Fellows Forum podcast episode, Dr. Richa Thakur, Palliative Care Physician and Hematology/Oncology Fellow at Northwell Health, speaks with Dr. Janet Abrahm, one of the founders of the field of palliative care in the United States. Dr. Abrahm shares insights into her career and research in palliative care, including: • How palliative care in oncology isn’t just for end of life—it’s for enha...

In this episode of Exploring Artificial Intelligence in Oncology, Dr. Waqas Haque sits down with Luis Valente, CEO and Co-Founder of iLoF, a digital health company pioneering a breakthrough AI platform to accelerate the future of personalized drug discovery and development.

In this episode of Exploring Artificial Intelligence in Oncology, Dr. Waqas Haque sits down with Dr. Tamir Wolf, Co-Founder and CEO of Theator, a company pioneering next-generation AI and computer vision technology to automatically capture and analyze surgical data in real time to generate actionable insights and improve surgical outcomes.

Investigating Axicabtagene Ciloleucel for R/R Central Nervous System Lymphoma: Lakshmi Nayak, MD by i3 Health

Combating Health Disparities Through More Equitable Screening: Chyke Doubeni, MD, MPH by i3 Health

Multicancer Early Detection - What's Your Opinion? with Chyke Doubeni, MD, MPH by i3 Health

The Latest Data on Zanidatamab for HER2-Positive Biliary Tract Cancer: Shubham Pant, MD by i3 Health

Biomarker Documentation in the Community Setting and Clinical Decision Support: Daniel Rubin, PharmD by i3 Health

Community Oncology Pharmacists - Their Crucial Role and Clinical Impact: Andrea Roman, PharmD, BCOP by i3 Health

Cancer and Careers - Empowering People with Cancer to Thrive in the Workplace: Rebecca Nellis, MPP by i3 Health

Exploring Association of FGFR3 Alterations in Urothelial Cancer: Arlene Siefker-Radtke, MD by i3 Health

Representing Symptom Research and Nursing at ASCO: Natalie Jackson-Carroll, PhD, APRN, FNP-C by i3 Health

Worth the Wait - Supporting Young Adult Cancer Survivors on the Path to Parenthood: Mike Scherer by i3 Health

Optimizing Sacituzumab Govitecan Tolerability in TNBC With Early Management: Antonio Llombart, MD by i3 Health

Understanding Lung Cancer Diagnostic Trends to Inform Therapeutic Development: Jess Paulus, SCd by i3 Health